» Articles » PMID: 38792879

Multimodal Treatment of Metastatic Rectal Cancer in a Young Patient: Case Report and Literature Review

Overview
Publisher MDPI
Specialty General Medicine
Date 2024 May 25
PMID 38792879
Authors
Affiliations
Soon will be listed here.
Abstract

Metastatic colorectal cancer requires a multidisciplinary and individualized approach. Herein, we reported the case of a young woman diagnosed with metastatic rectal cancer who received an individualized multimodal treatment strategy that resulted in a remarkable survival. There were several particular aspects of this case, such as the early onset of the disease, the successful use of conversion therapy, the application of liquid biopsy to guide treatment, and the specific nature of the bone metastasis. To offer more insights for navigating such challenges in patients with metastatic colorectal cancer, we have conducted a literature review to find more data related to the particularities of this case. The incidence of early onset colorectal cancer is on the rise. Data suggests that it differs from older-onset colorectal cancer in terms of its pathological, epidemiological, anatomical, metabolic, and biological characteristics. Conversion therapy and surgical intervention provide an opportunity for cure and improve outcomes in metastatic colorectal cancer. It is important to approach each case individually, as every patient with limited liver disease should be considered as a candidate for secondary resection. Moreover, liquid biopsy has an important role in the individualized management of metastatic colorectal cancer patients, as it offers additional information for treatment decisions.

References
1.
Tie J, Wang Y, Cohen J, Li L, Hong W, Christie M . Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study. PLoS Med. 2021; 18(5):e1003620. PMC: 8128260. DOI: 10.1371/journal.pmed.1003620. View

2.
Saad El Din K, Loree J, Sayre E, Gill S, Brown C, Dau H . Trends in the epidemiology of young-onset colorectal cancer: a worldwide systematic review. BMC Cancer. 2020; 20(1):288. PMC: 7137305. DOI: 10.1186/s12885-020-06766-9. View

3.
Amodio V, Mauri G, Reilly N, Sartore-Bianchi A, Siena S, Bardelli A . Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers. Cancers (Basel). 2021; 13(11). PMC: 8199207. DOI: 10.3390/cancers13112638. View

4.
Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C . Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo.... J Clin Oncol. 2007; 25(13):1670-6. DOI: 10.1200/JCO.2006.09.0928. View

5.
The Lancet Gastroenterology Hepatology . USPSTF recommends expansion of colorectal cancer screening. Lancet Gastroenterol Hepatol. 2020; 6(1):1. DOI: 10.1016/S2468-1253(20)30361-7. View